MX2022008339A - Metodo para producir una composicion que contiene un polipeptido con coloracion suprimida. - Google Patents
Metodo para producir una composicion que contiene un polipeptido con coloracion suprimida.Info
- Publication number
- MX2022008339A MX2022008339A MX2022008339A MX2022008339A MX2022008339A MX 2022008339 A MX2022008339 A MX 2022008339A MX 2022008339 A MX2022008339 A MX 2022008339A MX 2022008339 A MX2022008339 A MX 2022008339A MX 2022008339 A MX2022008339 A MX 2022008339A
- Authority
- MX
- Mexico
- Prior art keywords
- composition containing
- colored composition
- less colored
- containing polypeptide
- producing less
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020014739 | 2020-01-31 | ||
PCT/JP2021/003215 WO2021153723A1 (ja) | 2020-01-31 | 2021-01-29 | 着色を抑制したポリペプチドを含む組成物の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008339A true MX2022008339A (es) | 2022-08-04 |
Family
ID=77079170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008339A MX2022008339A (es) | 2020-01-31 | 2021-01-29 | Metodo para producir una composicion que contiene un polipeptido con coloracion suprimida. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230093028A1 (zh) |
EP (1) | EP4098751A4 (zh) |
JP (1) | JPWO2021153723A1 (zh) |
KR (1) | KR20220134541A (zh) |
CN (1) | CN115038793A (zh) |
AU (1) | AU2021213606A1 (zh) |
BR (1) | BR112022012467A2 (zh) |
CA (1) | CA3163829A1 (zh) |
IL (1) | IL295175A (zh) |
MX (1) | MX2022008339A (zh) |
TW (1) | TW202142694A (zh) |
WO (1) | WO2021153723A1 (zh) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006212033A (ja) * | 1995-11-17 | 2006-08-17 | Asahi Kasei Corp | 分化抑制ポリペプチド |
CN101724074B (zh) * | 2008-10-31 | 2012-06-27 | 苏州工业园区晨健抗体组药物开发有限公司 | 血管抑素受体β亚基人源化嵌合及人抗体、其制备及应用 |
EP2653548A1 (de) * | 2012-04-17 | 2013-10-23 | Greenovation Biotech GmbH | Verfahren zur Erhöhung der Sekretion rekombinanter Proteine |
US20130281355A1 (en) * | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
MA41294A (fr) * | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
TWI621628B (zh) | 2015-09-18 | 2018-04-21 | 日商中外製藥股份有限公司 | Il-8結合抗體及其用途 |
US20190119403A1 (en) * | 2016-03-31 | 2019-04-25 | University Of Southern California | Methods of constructing immunoglobulin fusion proteins inhibiting cathepsin b and compositions thereof |
TW202228778A (zh) * | 2016-06-17 | 2022-08-01 | 日商中外製藥股份有限公司 | 抗肌抑素抗體及使用方法 |
US20230103511A1 (en) | 2017-05-09 | 2023-04-06 | Bristol-Myers Squibb Company | Method of controlling the pink color generated during antibody manufacturing |
AR113142A1 (es) | 2017-09-29 | 2020-01-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo |
-
2021
- 2021-01-29 US US17/795,075 patent/US20230093028A1/en active Pending
- 2021-01-29 TW TW110103427A patent/TW202142694A/zh unknown
- 2021-01-29 CN CN202180011858.6A patent/CN115038793A/zh active Pending
- 2021-01-29 AU AU2021213606A patent/AU2021213606A1/en active Pending
- 2021-01-29 KR KR1020227025167A patent/KR20220134541A/ko unknown
- 2021-01-29 JP JP2021574143A patent/JPWO2021153723A1/ja active Pending
- 2021-01-29 BR BR112022012467A patent/BR112022012467A2/pt unknown
- 2021-01-29 WO PCT/JP2021/003215 patent/WO2021153723A1/ja unknown
- 2021-01-29 IL IL295175A patent/IL295175A/en unknown
- 2021-01-29 MX MX2022008339A patent/MX2022008339A/es unknown
- 2021-01-29 EP EP21747230.7A patent/EP4098751A4/en active Pending
- 2021-01-29 CA CA3163829A patent/CA3163829A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112022012467A2 (pt) | 2022-09-06 |
CN115038793A (zh) | 2022-09-09 |
JPWO2021153723A1 (zh) | 2021-08-05 |
KR20220134541A (ko) | 2022-10-05 |
WO2021153723A1 (ja) | 2021-08-05 |
TW202142694A (zh) | 2021-11-16 |
EP4098751A1 (en) | 2022-12-07 |
US20230093028A1 (en) | 2023-03-23 |
CA3163829A1 (en) | 2021-08-05 |
IL295175A (en) | 2022-09-01 |
EP4098751A4 (en) | 2023-06-21 |
AU2021213606A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200500462A (en) | Method for producing target substance by fermentation | |
TW200730623A (en) | Reprogramming and genetic modification of cells | |
NZ597334A (en) | Cell culture improvements | |
HK1113171A1 (en) | Medium and culture of embryonic stem cells | |
ATE414782T1 (de) | Verfahren zur herstellung von polypeptiden in mutierten aspergillus zellen | |
MX2022010521A (es) | Metodo para producir linfocitos citoliticos naturales a partir de celulas madre pluripotentes. | |
DE602005002829D1 (de) | Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen | |
UA92157C2 (ru) | Способ продуцирования гормона роста | |
ATE365793T1 (de) | Verfahren zur isolierung und kulturexpansion mesenchymaler stamm-/vorläuferzellen aus nabelschnurblut sowie verfahren zur differenzierung von aus nabelschnurblut stammenden mesenchymalen stamm-/vorläuferzellen in unterschiedliche mesenchymgewebe | |
WO2004090096A3 (en) | Methods for neural differentiation of embryonic stem cells using protease passaging techniques | |
ATE420198T1 (de) | Methylotrophe hefe,die eine zuckerkette eines säugers herstellt | |
EP1200557A4 (en) | PROCESS FOR THE MANUFACTURE OF ARTIFICIAL PLANT CHROMOSOMES | |
MX2022001959A (es) | Produccion de celulas t a partir de celulas madre pluripotenciales inducidas (ipscs) con inactivacion del gen de activacion de recombinacion (rag). | |
DK1495112T3 (da) | Cellekulturmedium | |
WO2016149821A8 (en) | Methods of making morphinan alkaloids and enzymes therefore | |
EP1687413B8 (en) | Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease | |
WO2022047222A3 (en) | Crispr/cas9 multiplex knockout of host cell proteins | |
MX2018010283A (es) | Metodo para producir factor de crecimiento de hepatocitos (hgf) activo. | |
MX2022008339A (es) | Metodo para producir una composicion que contiene un polipeptido con coloracion suprimida. | |
MY197429A (en) | Afucosylated antibodies and manufacture thereof | |
Scott et al. | Thermococcus kodakarensis provides a versatile hyperthermophilic archaeal platform for protein expression | |
CN102120966A (zh) | Ura3缺陷型毕赤酵母x-33菌株的构建及应用 | |
MX2021012649A (es) | Medio de cultivo celular para celulas eucarioticas. | |
CA3150477A1 (en) | MULTIPLICATION OF STEM CELLS CULTURED IN SUSPENSION IN A BIOREACTOR | |
NZ515762A (en) | Method of producing a heparin-binding protein by expressing it in a mammalian cell that can be cultured in anaerobic conditions |